- Conditions
- Dry Eye Syndromes, Dry Eye
- Interventions
- RGN-259, Placebo
- Drug
- Lead sponsor
- ReGenTree, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 5,307
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Atrial Fibrillation
- Interventions
- Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF
- Device
- Lead sponsor
- AtriCure, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 12
- States / cities
- San Francisco, California • Hartford, Connecticut • Clearwater, Florida + 9 more
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
- Interventions
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radionuclide Imaging, Selpercatinib, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 172
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PRM-151, placebo
- Biological · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- San Francisco, California • Denver, Colorado • New Haven, Connecticut + 7 more
- Conditions
- Dermatitis Atopic
- Interventions
- Amlitelimab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 42
- States / cities
- Scottsdale, Arizona • Fountain Valley, California • Fremont, California + 36 more
- Conditions
- Migraine
- Interventions
- Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 483 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Long Beach, California • National City, California + 36 more
- Conditions
- Haemophilus Influenzae Type b
- Interventions
- GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 4,003 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 63
- States / cities
- Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more
- Conditions
- Coronary Artery Disease, Myocardial Infarction
- Interventions
- IVL with Shockwave C2+ 2Hz Coronary IVL Catheter
- Device
- Lead sponsor
- Shockwave Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 18
- States / cities
- Huntsville, Alabama • La Jolla, California • Washington D.C., District of Columbia + 15 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Budesonide, placebo
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Alcohol Use Disorder, Alcohol-associated Liver Disease
- Interventions
- : Placebo for Probiotic, Lactobacillus Rhamnosus GG
- Drug · Dietary Supplement
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Pneumococcal Disease
- Interventions
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 1,511 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 41
- States / cities
- Tucson, Arizona • Fullerton, California • Oxnard, California + 33 more
- Conditions
- Pneumococcal Conjugate Vaccine
- Interventions
- 13-valent Pneumoccocal Conjugate Vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Louisville, Kentucky • The Bronx, New York + 1 more
- Conditions
- Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Germinoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Etoposide, Ifosfamide, Intensity-Modulated Radiation Therapy
- Radiation · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 149
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Downey, California + 115 more
- Conditions
- Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Assessment of Therapy Complications, Carboplatin, Filgrastim, Paclitaxel, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 75 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 357
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 245 more
- Conditions
- Allergic Fungal Rhinosinusitis
- Interventions
- Dupilumab SAR231893, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 11
- States / cities
- Tampa, Florida • Atlanta, Georgia • Louisville, Kentucky + 7 more
- Conditions
- COVID-19
- Interventions
- Acalabrutinib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 31
- States / cities
- Anniston, Alabama • Mobile, Alabama • Escondido, California + 25 more
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Interventions
- Inhaled treprostinil solution, Placebo solution
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Infections, Papillomavirus
- Interventions
- Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 11 Years to 18 Years · Female only
- Enrollment
- 1,330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more
- Conditions
- Blepharitis, Meibomianitis, Dry Eye
- Interventions
- COL-101 (doxycycline, USP) capsules, placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Naples, Florida • Louisville, Kentucky + 5 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Adalimumab
- Biological
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 846 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2011
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 66 more
- Conditions
- Breast Cancer
- Interventions
- Celecoxib
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 74
- States / cities
- Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more
- Conditions
- Newly Diagnosed Glioblastoma
- Interventions
- SurVaxM
- Biological
- Lead sponsor
- MimiVax, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- San Francisco, California • Miami, Florida • Louisville, Kentucky + 7 more
- Conditions
- Pulmonary Embolism and Thrombosis
- Interventions
- Ekosonic® Endovascular Device ultrasonic infusion catheter, Recombinant tissue plasminogen activator
- Device · Biological
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Tallahassee, Florida • Tampa, Florida + 13 more
- Conditions
- Catherization, Urinary Tract Infection Bacterial
- Interventions
- Povidone-Iodine, Sterile water
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky